2024
Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis.
Adelson K, Canavan M, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Cheng L. Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 20: 276-276. DOI: 10.1200/op.2024.20.10_suppl.276.Peer-Reviewed Original ResearchEnd-of-lifeSystemic anticancer therapyDay of deathIntensive care unit useIntensive care unitHealthcare utilizationEmergency departmentCombined chemo-immunotherapyEnd-of-life chemotherapy useAssociated with healthcare utilizationImmunotherapy useChemo-immunotherapyIncreased healthcare useEnd of lifeAdverse quality of lifeAssociated with higher EDCare unitQuality of lifeSystemic anti-cancer treatmentHospice useDay hospiceHospice enrollmentSEER-Medicare databaseUse of chemotherapyHealthcare useA Qualitative Study on the Impact and Feasibility of a Simulation-Based Program for Shared Decision-Making in Non–Small Cell Lung Cancer Care
Hakim H, Alexander C, Rudell E, Ingram M, Agrawal T, Peterson P, Davies M, Adelson K, Oliver B. A Qualitative Study on the Impact and Feasibility of a Simulation-Based Program for Shared Decision-Making in Non–Small Cell Lung Cancer Care. The Permanente Journal 2024, 28: 212-222. PMID: 39269215, PMCID: PMC11404665, DOI: 10.7812/tpp/23.152.Peer-Reviewed Original ResearchConceptsShared decision-makingOncology cliniciansSDM principlesPerceptions of shared decision-makingImprove health care outcomesPatient-centred care modelComprehensive cancer care centerLeadership buy-inPatient-centered careHealth care outcomesLung cancer careParticipants perceived benefitsHealth care environmentTeam member rolesNon-small cell lung cancer careThematic analysis of interview dataCancer care centerSimulation-based programAnalysis of interview dataCare modelCare outcomesCancer carePatient-centeredPatient experienceCare environmentBuilding Frontline Capability for Shared Decision-Making (SDM) in a Major Academic Oncology Center Caring for People With Non–Small Cell Lung Cancer: Performance Outcomes of a SDM Simulation Training Program
Alexander C, Hakim H, Rudell E, Ingram M, Agrawal T, Peterson P, Davies M, Adelson K, Oliver B. Building Frontline Capability for Shared Decision-Making (SDM) in a Major Academic Oncology Center Caring for People With Non–Small Cell Lung Cancer: Performance Outcomes of a SDM Simulation Training Program. The Permanente Journal 2024, 28: 200-211. PMID: 39269220, PMCID: PMC11404653, DOI: 10.7812/tpp/23.160.Peer-Reviewed Original ResearchConceptsShared decision-makingPractice settingsImplementation of shared decision-makingSDM trainingTraining programSimulation training programMultidisciplinary cliniciansCentered carePatient goalsPost-trainingClinician experienceFocus groupsClinical careSelf-efficacyParticipants' understandingClinician awarenessPostinterventionPilot studyActive participationParticipantsProgram designCareCliniciansBody of evidenceGrowing body of evidencePrognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma
Shimer S, Allen O, Yang C, Canavan M, Westvold S, Kim N, Morillo J, Parker T, Wallace N, Smith C, Adelson K. Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma. Journal Of Palliative Medicine 2024, 27: 879-887. PMID: 38990245, DOI: 10.1089/jpm.2023.0530.Peer-Reviewed Original ResearchGoals of carePrognostic awarenessQuality of lifeIllness understandingPrognostic understandingMultiple myelomaHematologic malignanciesAcute leukemiaFaith-based responseInformed treatment choicesChi-square testCohort of patientsLikelihood ratio chi-square testMount Sinai HospitalTreatment goalsMM cohortSinai HospitalCarePatient populationTreatment choiceHospitalized patientsHematologistsAssess discordanceLeukemiaPatientsSystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10: 887-895. PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratioSystemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Adelson K, Cheng L, Huang Y, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Canavan M. Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 42: 11092-11092. DOI: 10.1200/jco.2024.42.16_suppl.11092.Peer-Reviewed Original ResearchSystemic anticancer therapyCombined chemo-immunotherapyLiquid tumorsSolid tumorsDay of deathEmergency departmentRates of systemic therapySystemic anti-cancer therapySEER-Medicare databaseAnti-cancer therapyChemo-immunotherapyLT patientsSystemic therapyCI patientsSEER-MedicareST patientsIdentified patientsCost of drugsAssociated with higher costsEnd of lifeAnticancer therapyImmunotherapyChemotherapyPatientsTherapyCommunity Health Worker Navigation for Patients With Cancer: It Is Time to Scale up
Adelson K, Rocque G. Community Health Worker Navigation for Patients With Cancer: It Is Time to Scale up. Journal Of Clinical Oncology 2024, 42: 491-493. PMID: 38175984, DOI: 10.1200/jco.23.01723.Peer-Reviewed Original Research
2022
Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era
Canavan ME, Wang X, Ascha MS, Miksad RA, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era. JAMA Oncology 2022, 8: 1847-1849. PMID: 36264566, PMCID: PMC9585458, DOI: 10.1001/jamaoncol.2022.4666.Peer-Reviewed Original ResearchSelf-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings
Talcott W, Chen K, Peters G, Reddy K, Weintraub S, Mougalian S, Adelson K, Evans S. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e340. PMCID: PMC9595452, DOI: 10.1016/j.ijrobp.2022.07.1432.Peer-Reviewed Original ResearchOncology-hospitalist co-management: A model for efficient, high-quality care and education.
Morris J, Prsic E, Parker N, Weber U, Gombos E, Kottarathara M, Rothberg BE, Adelson K. Oncology-hospitalist co-management: A model for efficient, high-quality care and education. Journal Of Clinical Oncology 2022, 40: 1-1. DOI: 10.1200/jco.2022.40.28_suppl.001.Peer-Reviewed Original ResearchEarly discharge ratesReadmission ratesOncologist satisfactionIntervention teamHospitalist comanagementInpatient oncology serviceSmilow Cancer HospitalOutcome metricsHigher readmission ratesLength of stayMultidisciplinary steering groupHigh-quality careInternal medicine hospitalistsIllness scoresOncology teamCancer HospitalComparator groupOncology servicesPatient populationOutcome comparisonsCase volumeImprovement interventionsPDSA cyclesOncologistsPDSA 2Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsTriple-negative breast cancerNon-AA patientsEvent-free survivalPhase I/II clinical trialsClinical trialsNeoadjuvant chemotherapyOverall survivalAA patientsEarly-stage triple-negative breast cancerIncidence of irAEsPathologic complete response rateSignificant associationMultivariate logistic regression analysisTumor-infiltrating lymphocyte countsComplete response ratePrimary efficacy endpointPD-L1 statusProportional hazards modelLogistic regression analysisAfrican American womenEFS ratesNeoadjuvant immunotherapyEfficacy endpointAdverse eventsClinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Journal Of Clinical Oncology 2022, 40: 516-516. DOI: 10.1200/jco.2022.40.16_suppl.516.Peer-Reviewed Original ResearchImmune-related adverse eventsTriple-negative breast cancerMultivariate logistic regression analysisPD-L1 statusLogistic regression analysisAA raceOverall survivalPathologic responseClinical trialsBreast cancerEarly-stage triple-negative breast cancerIncidence of irAEsPhase I/II trialPathologic complete response rateSignificant associationPhase I/II clinical trialsBaseline body mass indexSafety of immunotherapyWeekly nab-paclitaxelCharlson Comorbidity IndexComplete response ratePrimary efficacy endpointPD-L1 expressionBody mass indexBreast cancer recurrenceSelf-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings
Talcott WJ, Chen K, Peters GW, Reddy KK, Weintraub SM, Mougalian SS, Adelson K, Evans SB. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: 30-38. PMID: 35598798, PMCID: PMC9119957, DOI: 10.1016/j.ijrobp.2022.05.002.Peer-Reviewed Original ResearchConceptsSelf-reported COVID-19 infectionCOVID-19 infectionOncology meetingsEra of vaccinationCOVID-19 positivityCOVID-19 positivity ratesOncology annual meetingsPerson attendeesAmerican SocietyCOVID-19Risk of diseasePerson meetingsPositivity rateNew COVID-19 infectionsResponse rateEvent ratesSocial distancing mandatesAuthor Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer 2022, 8: 17. PMID: 35115541, PMCID: PMC8814070, DOI: 10.1038/s41523-022-00392-3.Peer-Reviewed Original Research
2021
Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Xiang J, Prsic E, Adelson K, Prebet T. Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood 2021, 138: 3018. DOI: 10.1182/blood-2021-149300.Peer-Reviewed Original ResearchRefractory acute myeloid leukemiaAcute myeloid leukemiaPost-intervention groupLength of stayAdvanced acute myeloid leukemiaPalliative care consultHigh symptom burdenLines of therapyCare consultEnd of lifeDay of deathSame admissionCare escalationSymptom burdenHospice enrollmentHealthcare utilizationSymptom managementPrimary teamMyeloid leukemiaEastern Cooperative Oncology Group performance statusRelapsed/Refractory Acute Myeloid LeukemiaHigh-risk hematology patientsAdvance care planning documentationPalliative care remainsPalliative care useA Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)
Yardley DA, Young RR, Adelson KB, Silber AL, Najera JE, Daniel DB, Peacock N, Finney L, Hoekstra SJ, Shastry M, Hainsworth JD, Burris HA. A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). Clinical Breast Cancer 2021, 22: 269-278. PMID: 34824002, DOI: 10.1016/j.clbc.2021.10.011.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerCohort 2Cohort 1Breast cancerAndrogen biosynthesisAmylase/lipaseLimited clinical activityPrior chemotherapy regimenPrior chemotherapy regimensMedian treatment durationNausea/vomitingChemotherapy regimenChemotherapy regimensPrimary endpointObjective responseOverall survivalFemale patientsAndrogen receptorClinical activityGrade 3Targetable pathwaysPatientsTherapeutic targetAR modulationTreatment durationDifferences by race in systemic oncologic end-of-life (EOL) care among patients with cancer.
Adelson K, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Canavan M. Differences by race in systemic oncologic end-of-life (EOL) care among patients with cancer. Journal Of Clinical Oncology 2021, 39: 137-137. DOI: 10.1200/jco.2020.39.28_suppl.137.Peer-Reviewed Original ResearchBlack patientsWhite patientsAggressive EOL careRetrospective cohort studyPractice-level factorsPractice-level characteristicsRacial differencesDe-identified databaseLogistic regression modelsAnti-cancer therapyElectronic health recordsImmunotherapy eraCohort studyICI useOncologic treatmentPayer cohortHigh patientEOL careAdjusted ratesOutcome measuresEOL treatmentMedicaid coveragePatientsPhysician ratioRoutine practiceTrends in end-of- life (EOL) systemic oncologic treatment in contemporary clinical practice: Insights from real-world data.
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Trends in end-of- life (EOL) systemic oncologic treatment in contemporary clinical practice: Insights from real-world data. Journal Of Clinical Oncology 2021, 39: 253-253. DOI: 10.1200/jco.2020.39.28_suppl.253.Peer-Reviewed Original ResearchDay of deathReal-world practiceTraditional chemotherapyCancer treatmentStudy periodPractice-level factorsOverall healthcare utilizationSystemic cancer treatmentRates of chemotherapyDays of lifeDe-identified databaseContemporary clinical practiceLogistic regression modelsElectronic health recordsCancer care organizationsSystemic therapySystemic treatmentOncologic treatmentHealthcare utilizationImmune therapyTargeted therapyStratified analysisHigher total costsLife careOncolytic therapyImpact of an automatic palliative care consultation trigger on healthcare use in patients with relapsed/refractory acute myeloid leukemia.
Xiang J, Prsic E, Adelson K, Ozyck R, Prebet T. Impact of an automatic palliative care consultation trigger on healthcare use in patients with relapsed/refractory acute myeloid leukemia. Journal Of Clinical Oncology 2021, 39: 224-224. DOI: 10.1200/jco.2020.39.28_suppl.224.Peer-Reviewed Original ResearchRefractory acute myeloid leukemiaAcute myeloid leukemiaPost-intervention groupLength of stayPalliative care consultLines of therapyAdvance care planningCare consultHealthcare usePrimary teamMyeloid leukemiaCare planningAdvanced acute myeloid leukemiaPalliative care remainsPalliative care useSmilow Cancer HospitalECOG performance statusHigh-risk patientsHigher healthcare utilizationProspective cohort studyTertiary academic centerTimes/weekAML risk stratificationCriteria 1Fisher's t-testImpact of a Dedicated Cancer Urgent Care Center on Acute Care Utilization
Rothberg BE, Canavan ME, Mun S, Sedghi T, Carafeno T, Raucci M, Dest V, Sinanis N, Gross CP, Adelson KB. Impact of a Dedicated Cancer Urgent Care Center on Acute Care Utilization. JCO Oncology Practice 2021, 18: e129-e136. PMID: 34383579, DOI: 10.1200/op.21.00183.Peer-Reviewed Original ResearchConceptsUrgent care centersCare centerHospitalization ratesLarge tertiary academic centerAcute care useAcute care utilizationEmergency department presentationsTertiary academic centerEmergency room utilizationCancer care costsPeriod 1 yearProvider visitsActive therapyHospital admissionPrimary outcomeCare utilizationOncology patientsAcute careCare useClinic capacityPatient awarenessPhysician comfortClinical pathwayPatientsAcademic centers